Characteristics of the study cohort (N = 3274 recipients)
| Characteristic . | Value . |
|---|---|
| Recipients genotyped | 2991 (91%) |
| Donors genotyped | 3118 (95%) |
| Patient age at transplantation, y | |
| Median | 45 |
| Range | 0-78 |
| Donor age, y | |
| Median | 39 |
| Range | 0-83 |
| Diagnosis | |
| Acute leukemia | 1300 (40%) |
| Chronic myeloid leukemia | 720 (22%) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 595 (18%) |
| Chronic lymphocytic leukemia | 104 (3%) |
| Malignant lymphoma or multiple myeloma | 555 (17%) |
| Disease risk* | |
| Low | 699 (21%) |
| Intermediate | 925 (28%) |
| High | 1438 (44%) |
| Not classified | 212 (6%) |
| Donor–recipient sex | |
| Male to male | 1123 (34%) |
| Male to female | 734 (22%) |
| Female to male | 790 (24%) |
| Female to female | 626 (19%) |
| Donor type | |
| 10/10 HLA–matched sibling | 1827 (56%) |
| 10/10 HLA–matched unrelated | 1447 (44%) |
| Graft source | |
| Bone marrow | 1606 (49%) |
| Mobilized blood cells | 1668 (51%) |
| Conditioning | |
| Myeloablative <900 cGy total body irradiation | 1296 (40%) |
| Myeloablative ≥900 cGy total body irradiation | 1338 (41%) |
| Nonmyeloablative | 640 (20%) |
| Initial posttransplant immunosuppression | |
| Cyclosporine and methotrexate | 1643 (50%) |
| Cyclosporine and mycophenolate mofetil | 589 (18%) |
| Tacrolimus and methotrexate | 486 (15%) |
| Tacrolimus and mycophenolate mofetil | 160 (5%) |
| Cyclosporine or tacrolimus alone | 206 (6%) |
| Methotrexate or mycophenolate mofetil alone | 73 (2%) |
| Other (cyclophosphamide or anti-thymocyte globulin) | 117 (4%) |
| Characteristic . | Value . |
|---|---|
| Recipients genotyped | 2991 (91%) |
| Donors genotyped | 3118 (95%) |
| Patient age at transplantation, y | |
| Median | 45 |
| Range | 0-78 |
| Donor age, y | |
| Median | 39 |
| Range | 0-83 |
| Diagnosis | |
| Acute leukemia | 1300 (40%) |
| Chronic myeloid leukemia | 720 (22%) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 595 (18%) |
| Chronic lymphocytic leukemia | 104 (3%) |
| Malignant lymphoma or multiple myeloma | 555 (17%) |
| Disease risk* | |
| Low | 699 (21%) |
| Intermediate | 925 (28%) |
| High | 1438 (44%) |
| Not classified | 212 (6%) |
| Donor–recipient sex | |
| Male to male | 1123 (34%) |
| Male to female | 734 (22%) |
| Female to male | 790 (24%) |
| Female to female | 626 (19%) |
| Donor type | |
| 10/10 HLA–matched sibling | 1827 (56%) |
| 10/10 HLA–matched unrelated | 1447 (44%) |
| Graft source | |
| Bone marrow | 1606 (49%) |
| Mobilized blood cells | 1668 (51%) |
| Conditioning | |
| Myeloablative <900 cGy total body irradiation | 1296 (40%) |
| Myeloablative ≥900 cGy total body irradiation | 1338 (41%) |
| Nonmyeloablative | 640 (20%) |
| Initial posttransplant immunosuppression | |
| Cyclosporine and methotrexate | 1643 (50%) |
| Cyclosporine and mycophenolate mofetil | 589 (18%) |
| Tacrolimus and methotrexate | 486 (15%) |
| Tacrolimus and mycophenolate mofetil | 160 (5%) |
| Cyclosporine or tacrolimus alone | 206 (6%) |
| Methotrexate or mycophenolate mofetil alone | 73 (2%) |
| Other (cyclophosphamide or anti-thymocyte globulin) | 117 (4%) |
Low risk is chronic myeloid leukemia in chronic phase or myelodysplastic syndrome-refractory anemia; intermediate risk, acute leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma in remission; high risk, all others.